Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid

Supportive Care in Cancer

Volumn 20, Issue 1, 2012, Pages 87-93

  Shah, Sachin R ^a,b   Jean, Gary W ^a,b   Keisner, Sidney V ^a,b   Ussery, Sarah M Gressett ^b   Dowell, Jonathan E ^b,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Acute kidney failure; Bisphosphonates; Creatinine; Multiple myeloma; Prostatic neoplasm; Zoledronic acid

Indexed keywords

CREATININE; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CREATININE; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 83555163894     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-1067-7     Document Type: Article

References (15)

1. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157. doi:10.1200/JCO.2003.04.105 (Pubitemid 46606297)
2. Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma and breast carcinoma: a randomized, double-blind, multicenter comparative trial. Cancer 98:1735-1744. doi:10.1002/cncr.11701 (Pubitemid 37238631)
3. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468. doi:10.1200/JCO.2006.07.3361
4. Berenson JR, Hillner BE, Kyle RA et al (2002) American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719-3736. doi:10.1200/JCO.2002.06.037 (Pubitemid 34983232)
5. Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer 7:377-387. doi:10.1634/theoncologist.12-9-1035 (Pubitemid 33759002)
6. Markowitz GS, Fine PL, Stack JI et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281-289. doi:10.1046/j.1523-1755.2003.00071.x (Pubitemid 36714182)
7. Diel IJ, Weide R, Koppler H et al (2009) Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer 17:719-725. doi:10.1007/s00520-008-0553-7
8. Oh WK, Proctor K, Nakabayashi M et al (2007) The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 109:1090-1096. doi:10.1002/cncr.22504 (Pubitemid 46435387)
9. McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ (2006) Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model. J Support Oncol 4:524-529 (Pubitemid 46116997)
10. Chen L, Nikolas TL, Markowitz G et al (2006) Retrospective analysis of renal toxicity in breast cancer patients following zoledronic acid or pamidronate treatment. J Clin Oncol 24:564, 2006 ASCO Annual Meeting Proceedings Part I
11. Nickolas TL, Chen L, Markowitz G et al (2006) Renal toxicity associated with zoledronic acid and pamidronate in multiple myeloma patients: a retrospective study. J Clin Oncol 24:17515, 2006 ASCO Annual Meeting Proceedings Part I
12. Nordstrom BL, Langer C, Hussain A et al (2007) Renal function among cancer patients with bone metastases treated with zoledronic acid in a real world setting. J Clin Oncol 25:19540, 2007 ASCO Annual Meeting Proceedings Part I
13. Kyle RA, Yee GC, Somerfield MR et al (2007) American Society of Clinical Oncology 2007 Clinical Practice Guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464-2472. doi:10.1200/JCO.2007.12.1269 (Pubitemid 46999218)
14. Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2008
15. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. doi:10.1159/000180580